When such studies are at the design stage, the number of toxicokinetic time points required at each occasion has to be carefully considered as this impacts on the number of animals, particularly rodents, that are required for the study. Depending on the number of time points required at each occasion, the amount of blood required has to be carefully calculated to make sure the total stays within the limits [2] , as described in the following sections.
Maximum allowable blood volume removal
Established practices minimize the amount of stress placed on the animal and also limit excess pathology. For example, the maximum volume of blood that can be removed within a 24 h period from animals, usually rodents, assigned solely for toxicokinetic data generation is 15% of their total blood volume. When animals, usually non-rodents, are assigned for purposes of generating both toxicity and toxicokinetic data, established practices have also led to a further reduction (to 10% of the total blood volume) in the maximum amount of blood that can be removed within 24 h. Such good animal care practices allow for the restrictions on withdrawal of blood within a 21-day period to be widened slightly to 20% of the total blood volume as the maximum volume of blood that Dried blood spot sampling: practical considerations and recommendation for use with preclinical studies At present it is necessary to use animals to generate toxicokinetic data as part of preclinical safety studies. However, ethical standards require animal use to be carefully monitored and the principles of the 3Rs: replacement, reduction and refinement, to be considered and applied. Use of dried blood spot (DBS) samples, typically 10 to 20 µl, rather than the larger blood volumes required to obtain plasma samples, fully embraces the latter two principles of reduction and refinement. The use of DBS sampling enables the number of rodents per study to be reduced whilst also refining the way blood samples are taken from both rodents and non-rodents. The recent changes to the European Directive on the protection of animals used for scientific purposes favor DBS sampling becoming the standard for generation of toxicokinetic data, and imply that pharmaceutical companies will have to justify why plasma samples (and therefore larger blood volumes) are required for bioana lysis. Use of DBS samples has been, and is being, discussed widely within the pharmaceutical industry as the move away from taking large blood volumes becomes inevitable.
can be withdrawn from animals assigned solely for generation of toxicokinetic data, and 15% of the total blood volume as the maximum volume that can be withdrawn from animals assigned for generation of both toxicity and toxicokinetic data [2] .
In practical terms, these established practices limit blood sample collection from rodents (mice and rats) to the volumes detailed in Table 1 . The strain of rat also has to be considered as this can impact on the available blood volume. The two most common strains used by the pharmaceutical industry are Sprague Dawley and Han Wistar. Sprague Dawley rats are generally larger and heavier than those of the Han Wistar strain; body weights for each strain on day 1 and week 4 are presented in Table 1 .
When safety studies are carried out with rodents, typically additional groups are assigned solely for generation of toxicokinetic data in order that blood volumes of up to 0.5 ml can be collected to generate plasma for analysis. Therefore, the 15 and 20% limits apply. Based on the maximum amount of blood that can be withdrawn, studies conducted with mice require separate animals for each time point. A standard study design of one control and three treated groups with blood sampling at seven time points (three animals per time point) uses 168 mice to generate the required toxicokinetic data. These are in addition to the mice required for toxicity data generation. Table 2 describes a typical blood sampling design for generation of toxicokinetic data when a safety study is conducted with mice.
For safety studies conducted with rats, it is possible to take samples at two or three time points from each animal at each occasion. A standard study design with one control and three treated groups where blood sampling is required at seven time points (three animals per time point) requires 70 rats to generate the required toxicokinetic data. As with studies conducted with mice, these rats are in addition to those required for toxicity data generation. Table 3 describes a typical blood sampling design for generation of toxicokinetic data when a safety study is conducted with rats.
Safety studies carried out with non-rodents (rabbits, dogs and non-human primates) where similar blood volumes (0.3-0.5 ml) are required, do not need separate groups of animals in order to generate toxicokinetic data as complete toxicokinetic profiles can be taken from each animal. Therefore, the 10 and 15% limits are generally applicable, as presented in Table 4 .
When animals are subject to repeat blood sampling procedures, there may also be further local restrictions relating to the number of times a needle can be inserted into the vein of an animal. These restrictions are based on established practices aimed at minimizing the amount of stress under which an experimental animal is placed and typically will be in the region of no more than 12 occasions in each 26-h period.
A typical non-rodent study design with one control and three treated groups requires 24 animals (three per sex per group) to generate toxicity and toxicokinetic data, as presented in Table 5 .
Ethical considerations & the 3Rs
The European Commission published a new directive on the protection of animals used for scientific purposes in September 2010, which has strengthened the protection of animals still needed for research and safety testing [3] . The latest revision of Directive 86/609/EEC increases the emphasis on the requirement to perform ethical evaluation of all projects using animals prior to authorization of the project and seeks increased harmonization of such good practice across the EU. As it is not possible, at present, to completely stop the use of animals for safety testing, this Directive continues the established practice of ensuring they are only used when no other means are available. The 3Rs principle of replacing, reducing and refining animal testing is very much supported by the European Commission responsible for this Directive with emphasis on finding alternative 
Available blood volume:
Blood volume that can be removed without significant disturbance to the normal physiology of a laboratory animal.
3Rs:
The principles of replacement, refinement and reduction in animal use in research.
Dried blood spot: Means of storing whole blood samples in a dried format rather than the traditional liquid format. 
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Bioanalysis (2011) 3 (10) methods to testing on animals [4] . Where this is not possible the study design should be such that as few animals as possible are used, consistent with achieving the scientific objective of the study and that every opportunity is taken to refine the testing procedures in order to cause least harm to the animals. Use of dried blood spot (DBS) sampling satisfies the latter two categories: reduction in the number of animals required -particularly of rodents; and refinement in the way blood is taken from both rodents and non-rodents. This has also been a 'hot topic' of discussion within the pharmaceutical industry in recent years [5] [6] [7] . Use of DBS samples from rodent studies, as well as being statistically better in terms of removal of a lower volume of blood, also allows a complete whole blood toxicokinetic profile to be obtained from a single rodent. The different ways in which DBS sampling satisfies these two categories, compared with the current practice of taking larger blood volumes, is discussed in the following sections of this review.
Sampling procedures from rodents: large blood volumes (non-DBS)
Rats & mice: lateral caudal vein Typically rodents are placed for no longer than 15 min in a warming cabinet set at a temperature of 38°C in order to encourage vasodilation and The length and gauge of the needle to be used should be sufficient to allow a suitable flow of blood whilst not being too large to block or damage the blood vessel. Occlusive pressure can be applied to enable blood flow through the needle. The suction applied to the syringe should be just enough to draw the blood into the syringe, but not so much that the vein collapses. After collection of the blood sample, the needle is removed from the vein and the blood flow staunched using a gauze swab and slight pressure.
Sampling procedures from rodents: DBS samples
Collection of DBS samples from rodents is by a similar procedure utilizing the lateral caudal veins. However, the needle inserted is much finer and therefore less damage is caused to the vein and tail. It is prudent to have a warming cabinet present when collecting DBS samples from rats, as animals under 250 g (especially females that are smaller than males of the same age) may still require warming to dilate the vein. However, the warming period is very short, generally 2 to 3 min, compared with that used for collection of larger blood volumes. Mice still require warming for 10 to 15 min to ensure suitable vasodilation of the vein. The reduction in warming time makes the sampling procedure less stressful for the rats, therefore use of DBS samples is a refinement in blood sample collection procedures. DBS sample collection does not require the needle to stay in the vein throughout the procedure. If insertion of the fine gauge needle does not result in immediate blood flow, the needle can be withdrawn and the sample collected from the blood drop that forms at the site of the needle prick. It should be noted that this may result in undue contamination from the skin surface, however, this can also be seen as an additional refinement of sample collection, since generation of larger volumes may require reinsertion of the needle into the vein in order to withdraw the blood volume required.
A further refinement that DBS sample collection has over collection of larger volumes is that the blood flow often stops quicker once sample collection is complete as the puncture wound to the tail vein tissue is much smaller.
This procedure enables multiple or serial DBS samples to be harvested from rats and mice with minimal damage to the tails. Therefore, full toxico kinetic profiles can be generated from each rat, which generates both higher quality data and also allows these data to be directly compared with toxicity data observed during the in-life phase of the study. As DBS samples require less blood, typically 30-60 µl at each occasion (3 × 10 µl for mice; 3 × 20 µl for rats) compared with larger samples of 0.5 ml, this significantly reduces the stress to the animal caused by loss of blood. The smaller needle size, speed of the procedure and reduction in warming time for rats also serves to reduce the stress that rodents are subjected to. Use of a fine gauge needle (27G) has resulted in no evidence of injury to the tails despite taking 12 blood samples within 24 h from rats and six blood samples within 24 h from mice.
As well as the refinements to sample collection procedures, the use of DBS samples for generation of toxicokinetic data results in a reduction in the number of animals required. Long-term safety studies of 13 or 26 weeks in length do not require a separate set of rodents as those animals assigned for the collection of toxicity data can also be used for blood sample collection in order to generate toxicokinetic data. Depending on the study design this can result in up to a 50% reduction in the number of rats or mice required. Short-term study designs, such as rangefinding studies and the first regulatory studies, which are between 2 and 4 weeks in length, generally require a separate group of toxicokinetic animals to ensure that the small blood volumes withdrawn will not compromise histopathology and clinical pathology data. A separate group of toxicokinetic animals may not be required if the Sprague Dawley strain of rat is used, as it is a larger rodent. However, when the smaller Han Wistar strain is used, a separate group is almost always required. However, this separate group is much smaller than the group sizes required for collection of larger volumes. Serial DBS sample collection can be performed with rats, therefore only three rats per sex per group are required. For mice, six per sex per group (treatment groups) are to be recommended, especially if the time points are close together as mice require time to recover between each 15-min warming period; for the control group only three mice per sex are required as samples only need to be collected at C max and at 24 h after dosing. Examples of typical toxicokinetic study designs described above for mice and rats are presented in Table 6 .
Sampling procedures from rabbits & non-rodents: large blood volumes (non-DBS)
Rabbits: marginal ear vein Before larger (0.3 to 0.5 ml) blood samples can be collected from the marginal ear vein of the rabbit the fur is shaved or clipped to give clear visibility and access to the blood vessel. An irritant solution (e.g., 40% Vasolate ® ) is often applied over the blood vessel with a cotton wool pad. This causes dilation of the blood vessels, which become clearly visible and easier to access. This effect takes 3-4 min to appear and lasts approximately 8-10 min. Therefore, repeated blood sampling requires repeated application of irritant.
Dogs: jugular; non-human primate: femoral vein/artery
The jugular vein is the usual sampling site for dogs and the femoral vein for the non-human primate. In order to access these sampling sites, handlers are required to firmly restrain the dog with the head turned to expose the jugular vein. Access to the femoral vein is obtained by restraining the non-human primate in a dorsal recumbent position. At both sites the vein is occluded before inserting the needle and blood samples are withdrawn by applying negative pressure; however, care has to be taken not to apply too much pressure to avoid the vein collapsing. When the required sample has been collected, the needle is withdrawn and pressure applied to the puncture wound until bleeding has stopped. Bruising is a frequent observation recorded after blood sampling and is caused by the application of either too much, or too little, pressure at the site of sampling.
Sampling from rabbits & non-rodents: DBS samples
Rabbits: marginal ear vein Multiple DBS samples are also taken from the marginal ear vein of rabbits. Shaving or clipping will still be required for ease of access to the vein. However, there is no requirement to apply the Vasolate irritant as simple occlusion of the vein is the only requirement to raise the vein in order that the fine (27 gauge) needle can be inserted. After sampling, blood flow ceases within a few seconds of withdrawing the needle. Observation of the sampling site often reveals minimal or no bruising, even after repeated sampling from the same area. DBS, cephalic: dog DBS samples are taken from dogs by inserting a fine gauge needle into the cephalic vein, instead of the jugular vein. The dogs require only gentle restraint with one of the front paws extended. A small area is shaved to allow clear sight of the vein after slight occlusion. The dogs do not become unduly stressed by this procedure, as the restraint required is much less than when collecting larger sample volumes. In addition, repeated sampling results in only minimal, or no, bruising at the sampling site compared with collection of larger blood volumes.
DBS, cephalic: non-human primate
Blood for DBS samples is taken from non-human primates via the cephalic vein. The monkeys are sat on the handler's knee with gentle restraint and a front paw extended. If required, the sampling site is shaved. No occlusion is required to raise the vein and when the needle is withdrawn, blood flow ceases immediately without the need to apply pressure.
Anecdotal behavioural observations, including facial expression, fear and aggression responses, noted during sample collection have indicated the animals were more comfortable when the cephalic vein was used for blood sample collection. They also showed less aggression and there was little or no fear grimace as the needle was inserted. If animals are monitored, before and after blood sample collection for DBS, to look for any impact on normal activity in the pen and for any signs of irritation at the site of the puncture wound, few signs are generally recorded. Repeated DBS collection of up to 12 samples within a 24-h period has no impact on normal activity within the pen in any way and any irritation seen at the site of the puncture wound is minimal. If bruising does develop, this is generally very slight and dissipates within 24 h.
The use of DBS samples demonstrates a clear refinement in blood sample collection from the rabbit, dog and non-human primate compared with collection of larger blood volumes for the production of plasma.
Sample transfer to the DBS card
There are a number of ways blood can be transferred from the sampling site to the DBS card [8, 9] . The most efficient in terms of minimal blood volume collection is to transfer using glass capillary tubes. These are available in different sizes (10 and 20 µl being the most common) and are internally coated with anticoagulant (usually EDTA). The anticoagulant coating is required as blood used to prepare calibration standards and quality control samples always contains anti coagulant. Blood is drawn up the tube by capillary action directly from the drop that forms at the end of the sampling needle, or from the sample site if the needle is withdrawn. Standard practice is to use three of these coated capillaries, each drawing up the required amount of blood (usually 20 µl). The blood is then allowed to drop from the capillary tube onto the center of the guide circle on the DBS card. The capillary should not touch the card but remain a few millimeters above the card to allow even distribution of the blood drop across the card.
This procedure of directly transferring blood samples from the animal to the DBS card means only the blood volume that is subsequently analyzed is removed as there is no excess sample to be subsequently discarded. In addition, blood is spotted directly after collection, which
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Bioanalysis (2011) 3(10) minimizes the time between removal from the animal and the sample drying onto the DBS card. After spotting is complete, the DBS card is put to one side to dry and the next animal in the sequence is sampled. This organization of events will minimize any risk of spotting DBS samples from animal X onto a DBS card for animal Y.
An alternative procedure to transfer blood from the sampling site to the DBS card is to use an intermediary blood collection tube. A single volume of blood (typically 100-120 µl) is transferred from the sampling site into a blood collection tube (coated internally with anticoagulant). A repeating pipette is then used to spot three aliquots of 20 µl onto the DBS card to provide the samples for ana lysis. This procedure allows blood samples to be collected into tubes from all the animals at a particular occasion. These samples can then be spotted onto the DBS cards at a later stage in a different location by a separate group of technicians.
Once DBS samples have been spotted onto the DBS cards they are left to air dry for a minimum of 2 h after which each card is individually bagged. It should be noted that additional space for the card drying racks will be required in the sample collection area. A sachet of desiccant should always be included with each card to maintain the dry atmosphere, and thereby sample integrity, during storage prior to shipping and subsequent ana lysis.
Card selection & sample spotting considerations
One of the main considerations before starting the in-life phase of a safety study is confirmation of the type of DBS card to be used for sample collection. This requires some bioanalytical development and/or validation work to have been carried out in advance. Variations in the hamatocrit values for blood samples may also have an impact on the analytical results obtained [10] .
The first choice to make before the in-life study begins is the card format. Cards are available from a range of manufacturers and each has its own selection of card formats. Some of the options and examples available are:
Simple card style, no border, with cardboard fold-over flap for protection;
Unmarked paper or paper printed with guide circles to indicate where the blood spots should be placed;
Guide circle size (e.g., 10 mm is standard, 25 mm diameter may be used for particularly large sample volumes);
Ca ssette format, where the paper is surrounded by a cardboard or plastic border or frame. The cardboard surround format is compatible with certain automated card punching systems and appears to be the commonly used format for use in toxicology studies, with DBS cards the size of a credit card.
The cards with plastic borders also feature a retractable plastic cover that protects the blood spots from damage during storage and transport, and are available in a range of sizes;
The number of guide circles on the card can vary (e.g., cards printed with one, two, four and five circles are readily available). For toxicology studies that routinely require three blood spots per time point (one for initial analysis and a further two for duplicate reana lysis of anomalous results) the four circle format is commonly used. The fourth spot is retained as a spare;
Different card types give different blood spot sizes when the same volume of blood is used. For instance, different chemical treatments on the cards cause the blood to spread to differing extents and certain chemical treatments result in a 'halo' or lighter coloured region around the spot;
Circular cards with 12 spotting positions can be used with automated blood sampling instruments, which automatically collect blood from an animal at programmed times and deliver it to the card.
The second choice to make before the inlife study begins regards the use of chemically treated or untreated cards. Chemically treated cards have several advantages over untreated cards -some of the chemicals used render infectious pathogens inactive upon contact and can also aid in the efficient removal of the compound of interest from the card during the subsequent extraction process. A disadvantage of using chemically treated cards is that the materials used may occasionally cause a modification of ionization efficiency in LC-MS/MS assays and may not be optimal for the measurement of biotherapeutics. In addition, blank cards can be customized with user-defined treatments to address analytical issues such as analyte stability.
Once DBS samples have been received from an in-life study they need to be assessed as suitable for extraction using the validated bioanalytical method. Parameters that need to be assessed are:
Spot size -any spot significantly larger or smaller than that seen for the other samples in the study. If a particular blood spot is too small then it may not be physically possible to obtain the correct sized punch from the center of the spot to perform the bionalaytical assay. If no other replicate spots of this sample are available for ana lysis, then it may be possible to take a smaller punch from that spot and analyze it as a dilution sample, but this would raise the lower limit of quantification possible for this sample. A blood spot significantly larger than those for other samples might indicate that in error two blood spots have been placed at the same position on the card. If this larger blood sample has not spread across the card in proportion to the increased blood volume, then this would adversely affect the accuracy of the bioanalytical methodology for that particular sample. With DBS sampling it is obvious if a sample has not been collected properly as the spot size will vary;
Co-joined spots -if two spots have been applied too close to one another on the card then when they spread onto the card they will merge. This has an effect on how evenly the spots spread on the paper and may adversely affect the accuracy of the bioanalytical methodology;
Mis-shaped spots -if a spot has been placed too close to the cardboard border of a cassette style card, the blood will be prevented from spreading further in that direction and so an uneven distribution of blood will occur;
Smeared and splattered samples -these may have been accidentally smeared before the blood was completely dried or splattered during the spot application process;
Card damage -cards that are punctured or torn where the blood spot was applied may indicate that the sample was inappropriately applied to the card resulting in a compromised sample;
Appearance of clots in the DBS samples. Storage of DBS samples prior to and after ana lysis needs to be carefully considered. Depending on the chemical properties of the compound of interest and any potential metabolites present, plus the card type/format used to generate the samples, factors such as light intensity, temperature and humidity may affect the integrity of the samples. Shipment of DBS samples to another site for ana lysis offers cost savings as dried cards plus dessicant can be sent via the normal post, thereby negating the need for packaging in large boxes with dry ice or use of courier services.
Conclusion
In conclusion, the use of DBS samples with preclinical studies makes a significant contribution towards the principles of the 3Rs in that the number of rodents used for each study can be reduced and there is a significant refinement in blood sample collection procedures from rodents and non-rodents. DBS sampling requires only minimal restraint of the animal and use of a fine needle to puncture the lateral caudal vein (rodents), marginal ear vein (rabbits) or cephalic vein (dogs and non-human primates). There is little or no requirement to warm rodents to enhance blood flow, no requirement for application of irritants to the ears of rabbits, and for all species, blood flow ceases almost immediately after needle withdrawal, which significantly reduces the amount of bruising at the blood sampling site.
Future perspective
Use of DBS samples with preclinical studies will become more widespread in the future. This move will be driven by the changes to the European Directive, the need to comply with the principles of the 3Rs and also by pharmaceutical companies recognising the ethical and financial benefits. However, in order to move forward with DBS and preclinical studies, the analytical methodology has to be in place in advance of planning a live animal study so that the correct card format is selected. 
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